Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada

The Pediatric Infectious Disease Journal
Geneviève DeceuninckGaston De Serres

Abstract

In the province of Quebec, Canada, pneumococcal conjugate vaccine (PCV) is offered to all children aged less than 5 years, and a 2+1 schedule (2, 4, and 12 months) is recommended for low-risk infants, with other schedules including a lower number of doses for older children. To estimate PCV effectiveness against invasive pneumococcal disease (IPD). IPD cases in children aged 2-59 months and reported during the years 2005-2007 were eligible and uninfected controls were randomly identified in the provincial health insurance registry. Parents were interviewed by telephone and immunization records were reviewed. The PCV effectiveness was computed using unconditional logistic regression models adjusting for potential confounders. 180 IPD cases (60.4% of total reported) and 897 controls were included. Predictors of IPD risk were age, season, high-risk medical conditions, day-care attendance, and low family income. Overall PCV protection (> or =1 dose) against IPD caused by any serotype was 60% (95% CI: 38%-75%), and was 92% (83%-96%) against IPD caused by vaccine serotypes. Among low-risk children who received the recommended 2+1 schedule, 6 cases of vaccine failure occurred after the first dose, 1 case after the second dose, and no ...Continue Reading

References

Feb 15, 2001·The New England Journal of Medicine·J EskolaUNKNOWN Finnish Otitis Media Study Group
Oct 24, 2002·The Pediatric Infectious Disease Journal·Gordean L BjornsonUNKNOWN Canadian Paediatric Society/Health Canada Immunization Monitoring Program, Active
Mar 29, 2006·The Pediatric Infectious Disease Journal·David GoldblattElizabeth Miller
May 8, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Aurelio BarricarteMaite Arriazu
Feb 7, 2009·Expert Review of Vaccines·Ingeborg S Aaberge

❮ Previous
Next ❯

Citations

Dec 18, 2013·The Pediatric Infectious Disease Journal·Katherine L O'BrienCynthia G Whitney
Dec 31, 2010·Current Opinion in Pediatrics·Carlos G Grijalva, Stephen I Pelton
Apr 26, 2012·BMC Infectious Diseases·Stephanie R EarnshawDavid Strutton
Feb 4, 2010·BMC Pediatrics·William P HausdorffLode Schuerman
Feb 1, 2013·PloS One·Zitta B HarboeUNKNOWN Danish Pneumococcal Surveillance Collaborating Group
Dec 25, 2012·Emerging Infectious Diseases·Shamez N LadhaniElizabeth Miller
Sep 16, 2011·Vaccine·Gail L Rodgers, Keith P Klugman
Sep 16, 2011·Vaccine·Adriano ArguedasArturo Abdelnour
Jan 28, 2012·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Koh Cheng ThoonNancy Wen Sim Tee
Sep 4, 2012·Vaccine·S Ben-ShimolUNKNOWN Israeli Bacteremia and Meningitis Active Surveillance Group
Jun 12, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cheryl CohenUNKNOWN South African Invasive Pneumococcal Disease Case-Control Study Group
Mar 26, 2011·Expert Review of Vaccines·Bernard Fritzell, Mark A Fletcher
Jul 28, 2010·The Pediatric Infectious Disease Journal·Noga Givon-LaviRon Dagan
Mar 20, 2012·The Pediatric Infectious Disease Journal·Susanna EspositoUNKNOWN Italian Pneumococcal CAP Group
Oct 1, 2011·The Pediatric Infectious Disease Journal·Otto G VanderkooiUNKNOWN Canadian PCV13 Study Group
Mar 17, 2011·The Pediatric Infectious Disease Journal·María Catalina PírezAlicia Montano
Apr 12, 2014·Current Opinion in Pediatrics·Carol M KaoJoseph A Bocchini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.